The Texas Interprofessional Pharmacogenomics (IPGx)
Recruiting
Observational Study
Adverse Drug Reaction
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
45 and older
Sex
Any
Study type
Observational
Participants needed
50 (estimated)
Sponsor
Texas A&M University · Other
Who this trial is looking for
This trial is looking for patients who take multiple medications and may be at risk for bad reactions to those drugs. Participants will provide samples and share health information to help doctors improve medication safety.
Are You a Good Fit for This Trial?
Must not be takingImidazole antifungal medication
Rules you outActive liver diseaseHepatitis BHepatitis CAlzheimer's disease
You may be able to join if
I take 5 or more medications
I can give consent to participate
I can provide urine and saliva samples
I am at least 45 years old
You may not be able to join if
I have been treated for cancer in the last 5 years
I am currently in hospice care
I have had Hepatitis B or C
I have active liver disease or severe liver issues
I take imidazole antifungal medications
I do not want to participate or share my medical status
I have been diagnosed with Alzheimer's disease
I am pregnant
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clin…
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* People taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs
* Ability to give and comprehend the consent process.
* Consent to donate urine samples, genetic data through buccal swabs, unde…
Inclusion Criteria:
* People taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs
* Ability to give and comprehend the consent process.
* Consent to donate urine samples, genetic data through buccal swabs, undergo a comprehensive history and physical examination.
* All genders.
* Age 45 and over
Exclusion Criteria:
* Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded.
* Admitted to hospice.
* Patient has ever been diagnosed with Hepatitis B or C.
* Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score \>10, ALT or AST \>100U/L or an AST/ALT ratio \>2
* Patients taking imidazole antifungal medication.
* Declines to participate or interact with staff/share their medical status.
* A diagnosis of Alzheimer's disease
* Pregnant patients will be excluded
* Unable/unwilling to consent.
* Unable to verbally communicate and comprehend English/Spanish language.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.